Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesTreatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity
Osteoporosis International, 11/25/09
Musette P et al. – With early recognition and proper management, including immediate and permanent withdrawal of the culprit agent, accompanied by hospitalization and rehydration and systemic corticosteroids if necessary, the prognosis is good.
Methods- Reviewed cutaneous adverse reactions observed with antiosteoporotic agents, including information from case reports, regulatory documents, and pharmacovigilance
- Cutaneous adverse reactions range from benign reactions including exanthematous or maculopapular eruption (drug rash), photosensitivity, and urticaria to severe and potentially life-threatening reactions, angioedema, drug rash with eosinophilia and systemic symptoms (DRESS), Stevens Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN)
- Review of available evidence shows that cutaneous adverse reactions occur with all commonly used antiosteoporotic agents
- Reports of SJS and TEN for bisphosphonates, and of DRESS and TEN for strontium ranelate
- Severe reactions remain very rare (< 1 in 10,000 cases)
Today in Bone Metabolism...keeping you current
Receive free subspecialty "5-minute updates" via email
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
Osteoporosis International, 02/09/10
Effects of bone mineral density of the lumbar spine and prevalent vertebral fractures on the risk of immobility
Osteoporosis International, 02/09/10
Identifying and managing osteoporosis: An update
The Journal of Musculoskeletal Medicine, 02/08/10
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis
Seminars in Arthritis and Rheumatism, 02/09/10
Mycophenolate mofetil for localized scleroderma
International Journal of Clinical Rheumatology, 02/09/10
Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis
Osteoporosis International, 02/09/10
Article Search
Sponsor
Sponsor